Could quicker brain zaps lift depression faster?
NCT ID NCT07147218
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests whether an accelerated form of transcranial magnetic stimulation (TMS) can safely and effectively reduce depression symptoms in people with major depressive disorder. About 50 participants aged 15 and older will receive the treatment in an open-label design. The main goal is to see if depression scores improve after the accelerated sessions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
Aug 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
15 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female 2. 15 years and older 3. Able to provide informed consent or/and assent 4. Diagnosed with major depressive disorder (MDD) and currently experiencing a major depressive episode (MDE) 5. Adult participants failed to respond to at least one prior anti-depressant medication; for adolescent participants, TMS therapy is used as an adjunct treatment as stated in the FDA cleared indications, but failure to respond adequately to prior anti-depressant medication is not required 6. Participant prescribed TMS Therapy to treat MDD by his or her physician independent of potential participation in this clinical study 7. On a stable antidepressant treatment regimen (whether medication, therapy, other methods or no treatment at all) for at least the past 4 weeks and agrees to remain on the same treatment regimen throughout study enrollment 8. Willing to comply with all the study procedures, complete required assessments and visits, and be available for the duration of the study Exclusion Criteria: 1. Participants satisfy any one or more of the contraindications for TMS per current treatment guidelines as determined by the PI 2. Total MADRS score of \< 20 or PHQ-score \<10 at the screen or baseline visits 3. Current diagnosis of substance use disorder (Abuse or Dependence, as defined by DSM-V-TR), with the exception of nicotine dependence 4. Displaying symptoms of substance withdrawal 5. History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes 6. Any disorder which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within six months prior to screening 7. Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results 8. Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation 9. History of non-response to TMS or ECT 10. History of any implanted device or psychosurgery for depression 11. PI opinion: Considered at significant risk for suicide during the course of the study 12. Have any medical or psychological condition, that in the opinion of the referring psychiatrist or investigator, would prevent the participant from completing the study, put the participant at unacceptable risk or could interfere with study assessments or integrity of the data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brighter Neurotherapeutics
New York, New York, 10010, United States
-
New chapter TMS
Spokane, Washington, 99202, United States
-
TMS of the Carolinas
Charlotte, North Carolina, 28210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeting the brain's reward system: a new test for depression treatment
- Can brain activity reveal why some people with depression lose motivation and pleasure?
- Can sound, heat, and pressure rewire the depressed brain?
- Can two natural supplements boost antidepressants?
- Can a short talk therapy boost TB recovery?
- Can a targeted magnetic pulse rewire the depressed brain?